Klemens Egger

Postdoctoral Scientist

Data updated

Papers

5 publications

Trials

0 clinical trials

Research Footprint

Klemens Egger appears in 5 tracked papers (2024–2026), most studied alongside Ayahuasca, DMT and Placebo, across Healthy Volunteers, Neuroimaging & Brain Measures and Medicinal Chemistry & Drug Development.

Most-cited paper: Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat (14 citations).

Frequent co-authors: Milan Scheidegger, John Smallridge and Dominik Dornbierer.

Background & Research

Klemens Egger is a neuroscientist and postdoctoral scientist at the University of Zurich/University Hospital of Psychiatry Zurich. His research focuses on the pharmacology and neurobiology of DMT and harmine, including human clinical studies, fMRI, and FDG-PET investigations. He trained in chemistry and biomedical neuroscience, and his PhD work centered on psychedelic neuroimaging and drug interactions.